Skip to main content

AxCell Becomes First Firm to Use IBM Data-Mining Tool for Bioinformatics

NEW YORK, Aug. 16 - AxCell today said it will use IBM's DB2 Intelligent Miner technology to help its scientists determine how proteins interact in cellular-communication networks.

 

Though the deal represents the first time that IBM has seen its middleware applied as a bioinformatics tool, a company official stressed that the company will not be venturing to compete with traditional bioinformatics shops.

 

The Intelligent Miner software has been used in financial, insurance, and retail applications since it was introduced around six years ago, according to Sharon Nunes, director of IBM's life-science solutions division.

AxCell interim CEO Michael Becker, whose firm has been using IBM's DiscoveryLink software since last winter, said his company jumped at the chance to work with the computer giant when he learned it wanted to try the Intelligent Miner as a life-sciences application.

 

"It was a natural fit," said Becker. "It allowed us to access [IBM's] software and it provided IBM essentially with a reference point that it could use, so as they try to develop intelligently Miner for life-science customers that we can serve as a reference point for them."

 

Neither side would say how much, or whether, AxCell paid for the software, which the company essentially is beta testing for IBM, said Nunes.

 

"We will not be making our mining tools specifically available for [life-science] companies, but when we have a company that is interested in using them and testing them ... we're certainly going to sell to them," Nunes said in an interview.

 

But she stressed that IBM is not interested in setting its foot on bioinfomatics turf full-time. "Our focus is really on the architecture and the middleware," Nunes said. "We are not intending to go full-force into any area that has to do with bioinformatics tools."

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.